Stemson Secures Multi-Million Dollar Investment from Allergan

Today, Stemson Therapeutics announced a significant investment in its seed financing round by Allergan, a leading global pharmaceutical company. The investment will advance Stemson’s final product development in preparation for human clinical trials, and provide Allergan with a promising new product pipeline for its market leading Medical Aesthetics portfolio.  The investment with Stemson represents Allergan’s first step into iPSC-based cell therapy technology.  iPSC’s have the potential to become any cell type in the human body and hold great promise to deliver breakthrough regenerative medicine therapies in the future. Stemson Therapeutics is the first to discover how to differentiate iPSC’s into the cells responsible for inducing and controlling human hair follicle growth.

“Stemson believes we have the most promising biological approach to deliver a therapy which can generate net new hair follicles to replace those lost in people suffering from hair loss.  We are honored to have Allergan’s support, and we look forward to working together with the Allergan team in developing this exciting new therapy and taking it into clinical trial” said Geoff Hamilton, Chief Executive Officer and Co-Founder at Stemson Therapeutics.